We can’t show the full text here under this license. Use the link below to read it at the source.
The association between glucose‐dependent insulinotropic polypeptide and/or glucagon‐like peptide‐1 receptor agonist prescriptions and substance‐related outcomes in patients with opioid and alcohol use disorders: A real‐world data analysis
Links between diabetes drug prescriptions and substance use outcomes in patients with opioid and alcohol disorders
AI simplified
Abstract
Patients with prescriptions of glucose-dependent insulinotropic polypeptide (GIP) and/or glucagon-like peptide-1 receptor agonists (GLP-1 RA) had lower rates of opioid overdose and alcohol intoxication.
- GIP/GLP-1 RA prescriptions were linked to a 40% reduction in opioid overdose rates among patients with (OUD).
- Patients with opioid use disorder prescribed GIP/GLP-1 RAs had an adjusted incidence rate ratio (aIRR) of 0.60 for opioid overdoses.
- A 50% reduction in alcohol intoxication rates was observed in patients with (AUD) who received GIP/GLP-1 RAs.
- The aIRR for alcohol intoxication in AUD patients with GIP/GLP-1 RA prescriptions was 0.50.
- Protective effects of GIP/GLP-1 RAs on overdose and intoxication rates were consistent across subgroups, including those with type 2 diabetes and obesity.
AI simplified
Key numbers
0.60
Lower Rate of
Adjusted incidence rate ratio for patients with / prescriptions vs. those without
0.50
Lower Rate of
Adjusted incidence rate ratio for patients with / prescriptions vs. those without